Tradestie Institutional Equity Comparison Engine
VIVS vs MRNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MRNA Overall Edge
MRNA Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (61st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
MRNA
VIVS N/M vs MRNA 23.0x Fwd P/E
Growth & Margin Winner
MRNA
Op Margin -10117.0% vs -80.8% ยท YoY -51.4% vs +29.2%
Momentum & Technical Winner
MRNA
1Y -87.0% vs +699.9% ยท 52W Pos 5% vs 68%
Options & Structure Winner
MRNA
BREAKDOWN (N/A IV) vs CONSOLIDATION (61st %ile IV)
VIVS
NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap
$2.4M
1M Return
+64.69%
1Y Return
-86.99%
Forward P/E
N/M
Unified AI Score
36.8 / 100
SELL
Tech 5.0
Fund 38.0
Flow 50.0
Mom 50.0
MRNA
NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$199.33
+1.29% 1D
Market Cap
$79.6B
1M Return
-18.91%
1Y Return
+699.88%
Forward P/E
23.0x
Unified AI Score
39.5 / 100
SELL
Tech 15.0
Fund 42.0
Flow 68.0
Mom 46.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VIVS -86.99%
MRNA +699.88%
Spread: +786.87 pp (MRNA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VIVS Revenue | MRNA Revenue | VIVS Op. Margin | MRNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | $60M | -882.4% | -906.8% | VIVS |
| FY2020 | $0M | $800M | -977.9% | -95.0% | MRNA |
| FY2021 | N/A | $18.5B | N/A | 72.0% | MRNA |
| FY2022 | $0M | $19.3B | -765.3% | 48.9% | MRNA |
| FY2023 | $0M | $6.85B | -4792.2% | -61.9% | MRNA |
| FY2024 | $0M | $3.24B | -13840.4% | -121.9% | MRNA |
| FY2025 | $0M | $1.94B | -8761.1% | -158.1% | MRNA |
| FY2026 | $0M | N/A | -8768.7% | N/A | VIVS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VIVS | MRNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.4M | $79.6B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | -51.4% | +29.2% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -10117.0% | -80.8% | Higher Margin | MRNA |
| Net Profit Margin Profitability | 0.0% | -110.5% | Higher Margin | VIVS |
| Return on Equity (ROE) Capital Efficiency | -343.1% | -34.5% | Higher ROE | MRNA |
| 52-Week Range Position Momentum | 5% ($0โ$3) | 68% ($22โ$281) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 0.83ฮฒ ยท 480% Vol | 2.31ฮฒ ยท 97% Vol | Lower Realized Risk | MRNA |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 39.5 / 100 (SELL) | Higher Composite | MRNA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VIVS vs MRNA Buy Guide
VIVS
BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
MRNA
CONSOLIDATION
21d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
61st %ile
IV Regime
Elevated (60thโ80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VIVS nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.